Alendronate in kidney transplant patients: a single-center experience.

Introduction. Osteoporosis following a renal transplant is an important cause of morbidity. Several studies have demonstrated the efficiency of diphosphonates for the prevention and treatment of osteoporosis. Methods. We evaluated the effect of alendronate treatment on bone mineral density (BMD) in patients with osteoporosis (lumbar spine and/or hip t-scores &LE; -2.5). Two study groups were established: group A (n = 13), patients treated orally with vitamin D, calcium, and alendronate (70 mg/week) and group B (n = 12) patients receiving only vitamin D and calcium. The immunosuppression regimen mostly used was steroids and cyclosporine. BMD was determined at the lumbar spine and hip using a Hologic 4500 QDR densitometer at the start of treatment and after 1 year. Results. The study groups showed no significant differences in age, sex, menopause, or transplant time. Group A received a mean of 1.80 &PLUSMN; 1.3 μ g vitamin D/week and 1.3 &PLUSMN; 2.1 g calcium/d, compared to 1.1 &PLUSMN; 1 μ g and 1.25 &PLUSMN; 2.3 g, respectively for group B (NS). After a mean of 411.15 &PLUSMN; 107.75 days of treatment, a significant increase in BMD at the femoral neck was recorded in group A, but not at the level of the spine (+5.57% &PLUSMN; 3.5%, P <.05 and 0.42% &PLUSMN; 12%, NS, respectively). No significant changes were observed in group B (-1.45% &PLUSMN; 8% femoral neck and + 1.69% &PLUSMN; 3.5% hip, NS). Dyspepsia was reported by 7% of patients. Conclusions. In this preliminary analysis, alendronate produced, improvements are so far limited to an increased BMD in the hip.